|
Palo Alto, CA, April 18, 2003 — Telik, Inc. (Nasdaq:
TELK) announced that its quarterly conference call and webcast has
been scheduled for Thursday, April 24, 2003 at 4:30 p.m. Eastern
time. The call will follow the release of Telik’s first quarter
2003 financial results on April 24, 2003.
Participants may access the live webcast via Telik’s website
at www.telik.com or by telephone at (612) 332-0107. A replay of
the webcast will be available on the Telik website from approximately
8:30 p.m. Eastern time on April 24 through May 1, 2003.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TLK286, a tumor activated small molecule drug that is in a Phase
3 registration clinical trial in ovarian cancer and in clinical
trials in non-small cell lung, colorectal and breast cancer. TLK199
is in a Phase 1-2a trial in myelodysplastic syndrome, a form of
pre-leukemia. Telik’s product candidates were discovered
using its proprietary drug discovery technology, TRAP, which enables
the rapid and efficient discovery of small molecule drug candidates.
Additional information is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release, including statements regarding the potential
for TLK286 or TLK199 to treat one or more types of cancer. Telik
can give no assurance with regard to these statements. The application
of TRAP to additional new drug discovery may not yield additional
product candidates. TLK286 and TLK199 are in clinical development
and have not been approved for marketing, and there can be no assurance
that the clinical trials required to successfully develop these
compounds will have a successful outcome, or that regulatory approval
will be obtained. Telik is reliant on external manufacturing of
TLK286 and TLK199. More detailed information regarding factors that
may cause actual results to differ materially from the results expressed
or implied by statements in this press release may be found in Telik’s
periodic filings with the Securities and Exchange Commission. Telik
assumes no obligation to update any information in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
